In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study ( With these points in mind, we undertook a broad assessment of published clinical data, curating the body weight loss (% from baseline), glycosylated hemoglobin levels (HbA1c), and nausea responses (% patients reporting) from the SUSTAIN 3, SUSTAIN 7, SCALE Diabetes, SURPASS 2, and STEP 2 trials ( Figures 1AC )
Anti-diabetic drugs and weight loss in patients with type 2 diabetes
Can you stop GLP-1 medications without regaining weight
Sm t n (150mg): Cc k tt cho ni tit, sinh l n
In terms of glycemic control, GLP-1RAs reduce HbA1c by approximately 1.1% to 1.6%, compared to reductions of 0.6% to 1.1% observed with DPP-4is [59]
Clothes that fit tightly around your waist put pressure on your abdomen and the lower esophageal sphincter
